Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VolitionRX Ltd VNRX

Healthcare Medical Instruments & Supplies
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and... see more

Recent & Breaking News (NYSEAM:VNRX)

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

PR Newswire May 31, 2023

Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring

PR Newswire May 11, 2023

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update

PR Newswire May 10, 2023

VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update

PR Newswire May 5, 2023

VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.

PR Newswire April 26, 2023

VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update

PR Newswire March 15, 2023

VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update

PR Newswire March 10, 2023

VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock

PR Newswire February 22, 2023

VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock

PR Newswire February 17, 2023

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

PR Newswire February 16, 2023

Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation

PR Newswire February 16, 2023

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar

PR Newswire January 20, 2023

Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network

PR Newswire January 12, 2023

Volition Issues Business Review 2022

PR Newswire January 8, 2023

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

PR Newswire November 14, 2022

Volition Announces Clinical Research Study with Oncovet

PR Newswire November 14, 2022

Volition to Participate in a Lung Cancer Screening Study in France

PR Newswire November 10, 2022

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

PR Newswire November 3, 2022

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test

PR Newswire October 20, 2022

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

Accesswire October 11, 2022